Table of Contents
- What is Bosutinib?
- How Bosutinib Works
- Conditions Treated with Bosutinib
- Dosage and Administration
- Efficacy of Bosutinib
- Side Effects and Safety
- Monitoring During Treatment
- Special Considerations
What is Bosutinib?
Bosutinib, also known by its brand name Bosulif[1], is a medication used to treat certain types of blood cancer. It belongs to a class of drugs called tyrosine kinase inhibitors (TKIs)[1]. Bosutinib is an orally administered drug, which means it’s taken by mouth in the form of tablets[2].
How Bosutinib Works
Bosutinib works by targeting specific proteins in cancer cells called Src and Abl tyrosine kinases[1]. These proteins are involved in the growth and survival of cancer cells. By inhibiting these proteins, Bosutinib helps to slow down or stop the growth of cancer cells. This mechanism makes Bosutinib particularly effective against certain types of leukemia that are caused by a genetic abnormality called the Philadelphia chromosome[2].
Conditions Treated with Bosutinib
Bosutinib is primarily used to treat a type of blood cancer called Chronic Myeloid Leukemia (CML)[3]. Specifically, it’s used for:
- Newly diagnosed chronic phase CML: This is when CML is first detected and is in its earliest, most treatable stage[4].
- Chronic, accelerated, or blast phase CML in patients who have been previously treated with other TKIs[1]. This means Bosutinib can be used when other similar medications haven’t worked well enough.
Dosage and Administration
Bosutinib is typically taken once daily with food[2]. The usual starting doses are:
- 400 mg once daily for newly diagnosed chronic phase CML[1]
- 500 mg once daily for CML in patients previously treated with other TKIs[3]
Efficacy of Bosutinib
Clinical trials have shown that Bosutinib can be effective in treating CML. Some key findings include:
- Major Molecular Response (MMR): This is a measure of how well the treatment is working at the molecular level. In one study, 47.2% of patients achieved MMR at 12 months with Bosutinib[1].
- Complete Cytogenetic Response (CCyR): This means no cancer cells with the Philadelphia chromosome are detected in a bone marrow sample. In a study of newly diagnosed CML patients, 77.2% achieved CCyR at 12 months with Bosutinib[2].
- Overall Survival: Studies have shown high overall survival rates for patients treated with Bosutinib, with many patients still alive after several years of treatment[3].
Side Effects and Safety
Like all medications, Bosutinib can cause side effects. Common side effects include:
More serious side effects can include:- Liver problems[1]
- Low blood cell counts (including white blood cells, red blood cells, and platelets)[3]
- Fluid retention[1]
Monitoring During Treatment
While you’re taking Bosutinib, your doctor will regularly monitor your condition. This typically includes:
- Blood tests: To check your blood cell counts and liver function[3]
- Bone marrow tests: To check how well the treatment is working against the leukemia cells[2]
- Molecular tests: To measure the amount of leukemia cells in your body at a molecular level[1]
Special Considerations
There are a few important things to keep in mind when taking Bosutinib:
- Take with food: Bosutinib should be taken with food to help your body absorb the medication properly[2].
- Drug interactions: Bosutinib can interact with other medications. Always inform your doctor about all medications you’re taking, including over-the-counter drugs and supplements[1].
- Pregnancy and breastfeeding: Bosutinib may harm an unborn baby. If you’re pregnant, planning to become pregnant, or breastfeeding, discuss this with your doctor[1].
- Long-term treatment: Bosutinib is typically a long-term treatment. Some studies have followed patients for up to 5 years or more[1].
